Developing World Class
RNA Therapeutic Technologies

About Us

eTheRNA has developed a proprietary and integrated set of platform technologies that are overcoming the challenges facing the development of next generation mRNA therapeutics. Our platforms include mRNA construct design and optimization, proprietary lipid nanoparticles (LNP) and formulations, and in-house process engineering capabilities for mRNA drug substance manufacturing.

// OUR COMPANY

What We Do

Immunotherapies

Immunotherapies

Contract Manufacturing

Contract Manufacturing
// Stay up to date

Newsroom

// 21 June 2022

New agreement paves way for development of first African-owned COVID-19 vaccine

CAPE TOWN (SOUTH AFRICA) & BRUSSELS (BELGIUM), JUNE 21, 2022 – One year since the establishment of the mRNA Vaccine Technology Transfer Hub, a collaboration between two of the world’s leading biotech companies – Afrigen Biologics and the Univercells Group – was announced today. This agreement intends to pave the way for the development of the first-ever African-owned COVID-19 vaccine. The collaboration will focus on the development of a novel mRNA vaccine using intellectual property from the collaboration partners, as well as developing new IP, and is intended to supercharge access to the vaccine. Afrigen and Univercells will be supported in the collaboration by mRNA specialist eTheRNA.

// Our company

Come Join Us

Visit our careers site.

WE'D LIKE TO HEAR FROM YOU

eTheRNA engineering RNA_white
Europe
Europe

Corporate Headquarters — Galileilaan 19, 2845 Niel, Belgium

North America
North America

530 7th Avenue — Suite 902, New York, NY 10018 United States

Europe
Europe

Discovery Facility — Frieda Saeysstraat 1B, 3rd floor, 9052 Zwijnaarde - Gent, Belgium

Asia-Pacific
Asia-Pacific

Unit 605-07, 6/F Wing on Center, 111 Connaught Road Central, Sheung Wan, Hong Kong

info@etherna.be

Our Mailbox

+32 3 369 17 40

Our Phone

© 2022 eTheRNA | Studio Hanswijk